Search the Newsreel

RVLV Surges 33.1% in Three Months: Can Its Momentum Keep Building?

Revolve Group, Inc. RVLV shares have climbed 33.1% over the past three months, bringing the durability of the rally into focus. The move has coincided with faster sales growth, customer gains and better underlying merchandise margins. The operating backdrop is improving, but the stock …

Evolution Global Acquisition Ord Shs Class A (EVOX) Stock News Today

Evolution Global Acquisition Ord Shs Class A (EVOX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Evolution Global Acquisition Ord Shs Class A (EVOX), detailing future EPS and revenue growth estimates. It includes a stock overview with market capitalization and current stock price, along with a peer comparison. The forecast also covers expected …

Revolution Medicines, Inc. (RVMD) interactive stock chart

Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary

Evommune, Inc. reported no revenue and a net loss of $53.9 million for the second quarter of 2026, an increase from a $28.1 million net loss in the prior year. The company ceased development of EVO756 for chronic spontaneous urticaria but continues trials for …

Evommune Inc (EVMN) Stock News Today

This article provides current stock information for Evommune Inc (EVMN), including its market performance, market cap, and a note that more news will be coming soon. As of August 7th, the stock closed at 14.080 USD, up 5.49%. The platform offers news, analysis, financials, …

Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EOLS) 2026-08-06

This article announces that Evolus, Inc. (EOLS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported Q2 EPS of -$0.02, beating estimates by $0.02, and revenue of $84.08 million, a 21.18% year-over-year increase, beating estimates by $2.54 million. The …

Revolve Group, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Devon Energy Corp (DVN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Das prognostizieren Analysten für die Evonik Industries AG (ETR:EVK) nach der Veröffentlichung der Ergebnisse für das zweite Quartal

Evolus (EOLS) Stock Jumps On Margin Turn And EBITDA Momentum

GEVO Q2 Deep Dive: Carbon Strategy and North Dakota Expansion Drive Outlook

Did Evolution Mining’s (ASX:EVN) Diggers & Dealers Update Clarify Its Long-Term Growth Priorities?

Gevo Q2 Earnings Call Highlights

Gevo reported increased second-quarter revenue and significantly raised its 2026 adjusted EBITDA outlook, driven by strong performance in low-carbon fuels, expected tax credits, and new access to Canada's clean-fuel market. The company is advancing its North Dakota expansion to boost ethanol capacity and is …

Evolus Inc. Earnings Call Signals Confident Growth

Evolus, Inc. reported strong Q2 earnings with double-digit revenue growth and a third consecutive quarter of positive adjusted EBITDA, driven by its toxin franchise and growing international presence. Despite increased operating expenses and tariff uncertainty, the company raised its 2026 revenue guidance and reaffirmed …

Gevo, Inc. (GEVO) Reports Q2 Loss, Beats Revenue Estimates

Gevo, Inc. (GEVO) reported a Q2 loss of $0.01 per share, which beat the Zacks Consensus Estimate of a $0.02 loss, and revenues of $46.5 million, surpassing estimates by 2.23%. Despite underperforming the S&P 500 year-to-date, the company holds a Zacks Rank #2 (Buy) …

Gevo Q2 2026 slides: EBITDA outlook doubles to $60M

Gevo Inc. reported its Q2 2026 earnings, significantly raising its full-year adjusted EBITDA guidance to over $60 million, more than double its previous target. This improved outlook is driven by its carbon business and federal tax credit monetization, with the company expecting substantial positive …

Project write-downs drive steep Q2 loss at Gevo (Nasdaq: GEVO)

Gevo Inc. reported a significant Q2 2026 net loss of $176.9 million, primarily due to non-cash impairment charges of $135.8 million on discontinued projects and a $39.8 million allowance for credit losses. Despite increased revenue, the company underwent a strategic review, prioritizing its ethanol …

Gevo (GEVO) Stock Rises on Q2 2026 Earnings

Gevo, Inc. (GEVO) reported Q2 2026 revenue of $46.5 million, up 7.1% year-over-year, which was in line with analyst expectations. Despite this revenue growth, the company experienced a significant operating loss of $171.7 million and a net loss of $176.9 million, resulting in a …

Gevo (GEVO) insider files to sell equity compensation shares

An insider at Gevo, Inc. (GEVO), Oluwagbemileke Yusuf Agiri, has filed a Form 144 notice to sell up to 18,223 shares of common stock, valued at approximately $28,033.63. These shares originated from restricted stock awards received as equity compensation in August 2023. The filing …

Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside

Revolution Medicines, Inc. (RVMD) has seen its average price target raised from $207.16 to $216.4 by 20 analysts, with forecasts ranging from $151 to $263 per share. This updated target suggests a potential 10% upside based on the Aug. 5 closing price. The consensus …

Gevo Exits South Dakota Ethanol and SAF Activities After $176M Charge

Gevo reported its second-quarter 2026 financial results, including a GAAP net loss of $(176.9) million due to a $176 million non-cash impairment charge from exiting South Dakota ethanol and SAF projects. The company raised its full-year 2026 non-GAAP Adjusted EBITDA outlook to over $60 …

Evolent Health Inc (EVH) (Q2 2026) Earnings Call Highlights: Revenue Surges 31% and Guidance ...

Key Points Interested in Evolent Health, Inc? Here are five stocks we like better. Evolent raised its 2026 outlook after Q2 revenue rose 31% sequentially to $653 million and adjusted EBITDA increased 27% to $28 million. Full-year revenue guidance is now $2.6 billion–$2.7 billion, …

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

Revolution Medicines RVMD reported an adjusted loss of $2.34 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.93. The adjusted figure excluded a non-cash charge of $151 million tied to a change in the …

Devon CEO on divestiture plan: ‘There is no shortage of incoming phone calls’

Devon Energy CEO Clay Gaspar stated there is significant interest from potential buyers for assets the company might divest following its acquisition of Coterra Energy. While Gaspar would not confirm specific sales, he indicated that an update on portfolio plans would be provided this …

Evolus Inc (EOLS) News, Articles, Events & Latest Updates

This article provides a compilation of recent news, articles, and updates concerning Evolus Inc (EOLS). Key highlights include Evolus reporting strong Q2 2026 financial results with positive adjusted EBITDA, expanding partnerships, and announcing future earnings report dates. The company also reported inducement grants of …

SGC or RVLV: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Textile - Apparel sector have probably already heard of Superior Group (SGC) and Revolve Group (RVLV). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. …

Evolv Technologies Holdings, Inc. Class A Share Price Live Today – NASDAQ:EVLV Stock Price, Chart, News, History

This article provides a detailed overview of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) Class A share performance, fundamentals, and historical returns as of August 8, 2026. It highlights the current stock price, market capitalization, P/L statements, and key indicators like revenue and profit margin. …

DVN Q2 Earnings Call Puts Synergies and Portfolio Review in Focus

Devon Energy Corporation DVN emphasized merger integration, tighter execution and a portfolio review on its second-quarter 2026 earnings call. Management addressed post-merger strategic concerns. The message was disciplined urgency: deliver synergies, clarify the asset base and raise shareholder returns without disrupting operations. DVN Tightens …

Compared to Estimates, Devon Energy (DVN) Q2 Earnings: A Look at Key Metrics

Devon Energy (DVN) reported $7.42 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 73.1%. EPS of $1.57 for the same period compares to $0.84 a year ago. The reported revenue represents a surprise of +17.76% over the Zacks …

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates

Evolent Announces Second Quarter 2026 Results

Emat stock hits 52-week low at 2.74 USD By Investing.com

Evolution Metals & Technologies (EMAT) stock has hit a new 52-week low of 2.74 USD, reflecting a 74.45% decline over the past year due to sector challenges and investor concerns. Despite this downturn, the company recently regained Nasdaq compliance after filing its delayed quarterly …

Hotline Miami publisher Devolver Digital shares plunge on AIM exit plan

Evotec and Odyssey Pair AI With Lab Tests for Immune Diseases

Evotec has announced an AI-enabled R&D collaboration with Odyssey Therapeutics to discover new small molecule treatments for autoimmune and inflammatory diseases. The partnership will leverage Evotec's integrated discovery platform, advanced screening, and AI-driven data science to accelerate the identification of validated hit series. Evotec …